{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:29Z","timestamp":1772165909123,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2018 Yeungnam University Research Grant","award":["218A580038"],"award-info":[{"award-number":["218A580038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sequential therapy from bone-forming medication to resorptive agents is reportedly effective for patients with severe osteoporosis. The objective of this study is to determine the impact of implementing short-term teriparatide (TPTD) intervention before denosumab (DMab) therapy compared with DMab therapy alone for 1\u2009year after hip fracture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the medical records and radiographs of patients who were treated due to osteoporotic hip fracture. TPTD was administered to 22 patients for an average of 12.1\u2009weeks after which the intervention was switched to DMab therapy for 12\u2009months (group 1). DMab alone was administered to 16 patients for 12\u2009months (group 2). Bone mineral density (BMD) was evaluated before and after treatment at the 1-year follow-up. The improvement of BMD in hip and spine was compared with the levels of bone turnover marker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The difference in femoral neck BMD was 0.005\u2009\u00b1\u20090.04 in group 1 and\u2009\u2212\u20090.014\u2009\u00b1\u20090.10 in group 2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.442). The difference of spine BMD was 0.043\u2009\u00b1\u20090.05 in group 1 and 0.052\u2009\u00b1\u20090.06 in group 2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.640). BMD of the spine improved significantly in groups 1 and 2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). There was no statistical difference in C-terminal telopeptide and osteocalcin level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Short-term TPTD administration followed by DMab alone was effective only in improving spine BMD. Short-term treatment with TPTD caused mild improvement in femur neck BMD compared with DMab alone. However, further research with a longer duration of TPTD treatment is warranted, as our findings lack statistical significance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12891-020-03771-8","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T11:02:33Z","timestamp":1605351753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study"],"prefix":"10.1186","volume":"21","author":[{"given":"Chan Ho","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Il","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4906-9709","authenticated-orcid":false,"given":"You-Sung","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,14]]},"reference":[{"key":"3771_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00223-011-9545-6","volume":"90","author":"H Hagino","year":"2012","unstructured":"Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int. 2012;90:14\u201321.","journal-title":"Calcif Tissue Int"},{"key":"3771_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3346\/jkms.2014.29.7.992","volume":"29","author":"KH Lee","year":"2014","unstructured":"Lee KH, Kim JY, Yim SJ, Moon DH, Choi GH, Moon KH. Incidence and risk factors of subsequent hip fractures in Korea: multicenter study. J Korean Med Sci. 2014;29:992\u20134.","journal-title":"J Korean Med Sci"},{"key":"3771_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/2151458515618490","volume":"7","author":"MA Moll","year":"2016","unstructured":"Moll MA, Bachmann LM, Joeris A, Goldhahn J, Blauth M. Parameters pointing at an increased risk for contralateral hip fractures: systematic review. Geriatr Orthop Surg Rehabil. 2016;7:45\u201361.","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"3771_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1471-2474-12-105","volume":"12","author":"J Panula","year":"2011","unstructured":"Panula J, Pihlajam\u00e4ki H, Mattila VM, Jaatinen P, Vahlberg T, Aarnio P, et al. Mortality and cause of death in hip fracture patients aged 65 or older - a population-based study. BMC Musculoskelet Disord. 2011;12:105.","journal-title":"BMC Musculoskelet Disord"},{"key":"3771_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1302\/2058-5241.4.180018","volume":"4","author":"S Tanaka","year":"2019","unstructured":"Tanaka S. Molecular understanding of pharmacological treatment of osteoporosis. EFORT Open Reviews. 2019;4:158.","journal-title":"EFORT Open Reviews"},{"key":"3771_CR6","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu KN, Lie JD, CKV W, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. Pharmacy Ther. 2018;43:92.","journal-title":"Pharmacy Ther"},{"key":"3771_CR7","doi-asserted-by":"publisher","unstructured":"Bubbear JS. Atypical femur fractures in patients treated with bisphosphonates: identification, management, and prevention. Rambam Maimonides Med J. 2016;7. https:\/\/doi.org\/10.5041\/RMMJ.10259.","DOI":"10.5041\/RMMJ.10259"},{"key":"3771_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1759720X11424220","volume":"3","author":"PD Miller","year":"2011","unstructured":"Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis. 2011;3:271\u201382.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3771_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, Fuleihan GE-H, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis patients after long-term bisphosphonate treatment. J Bone Miner Res. 2016;31:16\u201335.","journal-title":"J Bone Miner Res"},{"key":"3771_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jbm4.10041","volume":"2","author":"BZ Leder","year":"2018","unstructured":"Leder BZ. Optimizing sequential and combined anabolic and Antiresorptive osteoporosis therapy. JBMR Plus. 2018;2:62\u20138.","journal-title":"JBMR Plus"},{"key":"3771_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1210\/jc.2015-3698","volume":"101","author":"F Cosman","year":"2016","unstructured":"Cosman F, Dempster DW, Nieves JW, Zhou H, Zion M, Roimisher C, et al. Effect of Teriparatide on bone formation in the human femoral neck. J Clin Endocrinol Metab. 2016;101:1498\u2013505.","journal-title":"J Clin Endocrinol Metab"},{"key":"3771_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.5312\/wjo.v6.i6.457","volume":"6","author":"S Babu","year":"2015","unstructured":"Babu S, Sandiford NA, Vrahas M. Use of Teriparatide to improve fracture healing: what is the evidence? World Journal of Orthopedics. 2015;6:457.","journal-title":"World Journal of Orthopedics"},{"key":"3771_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet. 2015;386:1147\u201355.","journal-title":"Lancet."},{"key":"3771_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/boneres.2017.2","volume":"5","author":"A Takakura","year":"2017","unstructured":"Takakura A, Lee J-W, Hirano K, Isogai Y, Ishizuya T, Takao-Kawabata R, et al. Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats. Bone Research. 2017;5:1\u201314.","journal-title":"Bone Research"},{"key":"3771_CR15","doi-asserted-by":"crossref","unstructured":"Lindsay R. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int. 2016;16.","DOI":"10.1007\/s00198-016-3534-6"},{"key":"3771_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jocd.2017.05.007","volume":"20","author":"JN Tsai","year":"2017","unstructured":"Tsai JN, Jiang LA, Lee H, Hans D, Leder BZ. Effects of Teriparatide, Denosumab, or both on spine trabecular microarchitecture in DATA-switch: a randomized controlled trial. J Clin Densitom. 2017;20:507\u201312.","journal-title":"J Clin Densitom"},{"key":"3771_CR17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie S-AM, Zhu Y, Foley K, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99:1694\u2013700.","journal-title":"J Clin Endocrinol Metab"},{"key":"3771_CR18","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","volume":"17","author":"NK Arden","year":"2006","unstructured":"Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int. 2006;17:1626\u20139.","journal-title":"Osteoporos Int"},{"key":"3771_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00198-016-3888-9","volume":"28","author":"RT Burge","year":"2017","unstructured":"Burge RT, Disch DP, Gelwicks S, Zhang X, Krege JH. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int. 2017;28:799\u2013809.","journal-title":"Osteoporos Int"},{"key":"3771_CR20","first-page":"7","volume":"5","author":"EA Almirol","year":"2016","unstructured":"Almirol EA, Chi LY, Khurana B, Hurwitz S, Bluman EM, Chiodo C, et al. Short-term effects of teriparatide versus placebo on bone biomarkers, structure, and fracture healing in women with lower-extremity stress fractures: a pilot study. J Clin Transl Endocrinol. 2016;5:7\u201314.","journal-title":"J Clin Transl Endocrinol"},{"key":"3771_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.13004\/kjnt.2019.15.e13","volume":"15","author":"JH Kang","year":"2019","unstructured":"Kang JH, Yang SM, Im SB, Jeong JH. Can three months of Teriparatide be one of treatment options for osteoporotic vertebral compression fracture patients? Korean J Neurotrauma. 2019;15:19\u201327.","journal-title":"Korean J Neurotrauma"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-020-03771-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T11:02:42Z","timestamp":1605351762000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-020-03771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3771"],"URL":"https:\/\/doi.org\/10.1186\/s12891-020-03771-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-37191\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37191\/v2","asserted-by":"object"}]},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,14]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study protocol was reviewed and approved by the Institutional Review Board of Yeungnam University Hospital (approval No. YUMC 2019\u201310-025). The need to obtain informed consent was waived because of the retrospective nature of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"751"}}